Moleculin Reports 3x Higher Remission Rates for Annamycin in Pivotal AML Trial
MBRX has more than doubled off its 52-week low of $1.79 on elevated volume (4.6× avg).
Summary
Moleculin Biotech announced positive unblinded interim results from its pivotal Phase 2/3 MIRACLE trial for Annamycin in relapsed/refractory AML, showing significantly higher complete remission rates compared to the control arm.
Key Events · Product Development and Regulatory · MBRX
-
Positive Interim Efficacy Results
Annamycin treatment arms demonstrated complete remission (CR) rates of 43% and 36%, significantly outperforming the control arm's 12% CR rate in relapsed or refractory acute myeloid leukemia (R/R AML) patients.
-
Pivotal Trial Continuation Recommended
The Independent Data Monitoring Committee (iDMC) unanimously recommended continuing the Phase 2/3 MIRACLE trial, citing a strong numeric trend favoring the experimental treatment arms, despite not yet reaching statistical significance at this early interim analysis.
-
Enrollment Progress
Part A of the MIRACLE trial has enrolled 67 of the targeted 90 patients (approximately 74%), as the company progresses towards selecting the optimal Annamycin dose for the pivotal portion of the study.
Analysis · MBRX · Life Sciences
Moleculin Biotech announced highly positive unblinded interim efficacy results for its lead drug candidate, Annamycin, in a pivotal Phase 2/3 trial for relapsed or refractory AML. The significant improvement in complete remission rates (3x higher than control) provides crucial validation for the drug's potential. This positive clinical data is particularly critical for the company, which recently issued a 'going concern' warning and needs substantial new capital. Strong trial results are essential for attracting the financing required to continue operations and advance Annamycin towards potential approval.
At the time of this filing, MBRX was trading at $3.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.1M. The 52-week trading range was $1.79 to $24.00. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.